Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers Sells 11,033 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 11,033 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $1,000,582.77. Following the completion of the transaction, the director now directly owns 165,017 shares in the company, valued at $14,965,391.73. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Blueprint Medicines Stock Performance

NASDAQ:BPMC opened at $94.79 on Thursday. The company has a fifty day simple moving average of $86.06 and a two-hundred day simple moving average of $72.75. The company has a market cap of $5.80 billion, a price-to-earnings ratio of -11.34 and a beta of 0.63. The company has a quick ratio of 3.66, a current ratio of 3.76 and a debt-to-equity ratio of 1.60. Blueprint Medicines Co. has a 52 week low of $41.54 and a 52 week high of $101.00.

Blueprint Medicines (NASDAQ:BPMC) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, topping the consensus estimate of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The company’s quarterly revenue was up 85.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.65) earnings per share. As a group, equities analysts anticipate that Blueprint Medicines Co. will post -5.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $114.00 price target on shares of Blueprint Medicines in a research report on Friday, February 16th. Raymond James lifted their price target on shares of Blueprint Medicines from $85.00 to $100.00 and gave the company a “strong-buy” rating in a research report on Friday, December 22nd. Citigroup lifted their price target on shares of Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a research report on Friday, February 16th. Wells Fargo & Company lifted their price target on shares of Blueprint Medicines from $86.00 to $115.00 and gave the company an “overweight” rating in a research report on Tuesday, December 19th. Finally, Stifel Nicolaus lifted their price target on shares of Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Four equities research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Blueprint Medicines currently has an average rating of “Hold” and a consensus target price of $85.43.

Hedge Funds Weigh In On Blueprint Medicines

Institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. grew its stake in shares of Blueprint Medicines by 63.4% in the third quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 329 shares in the last quarter. Pinebridge Investments L.P. acquired a new position in shares of Blueprint Medicines in the second quarter worth $46,000. Cutler Group LLC CA grew its stake in shares of Blueprint Medicines by 1,685.7% in the third quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 944 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of Blueprint Medicines in the fourth quarter worth $57,000. Finally, Dark Forest Capital Management LP acquired a new position in shares of Blueprint Medicines during the first quarter worth $63,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.